Page 20 - நினைவகம் ஸ்லோன் கெட்டரிங் புற்றுநோய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: May 14, 2021 By Brandon May Foresite Labs-incubated company Interline Therapeutics  announced Thursday that it had raised $92 million in a financing round co-led by Foresite Capital and ARCH Venture Partners. The funding, which has officially launched the company, will be geared toward the development of therapies that correct dysfunctional protein communities to treat various diseases.  The $92 million financing round is a combination of seed and Series A funding. The newly launched company says the proceeds will be funneled to facilitate the expansion of its research platform and advance a total of six preclinical therapeutic programs.  Interline Therapeutics will specifically use genomics, proteomics, structural biology, and computational chemistry to “map and modulate protein communities” to construct a precision medicine platform focused on genomics, protein communities, and modulators of these communities. These three pillars form the basis of

United statesSan franciscoKinnate biopharmaWarburg pincusJune leeVikram bajajZachary sweeneyUniversity of californiaInterline therapeutic coMemorial sloan kettering cancer centerInterline therapeuticsForesite capitalMemorial sloan kettering cancerTherapeutic co founderChief executive officerDenali therapeutics